Agenus Inc.

The current price of AGEN is $6.44 — it has decreased by 7.60% since the previous close. Data as of Nov 5, 2026.

AGEN is down 6.26% over the past week, down 26.23% over the past month and up 74.53% over the past year. The price is above its 200-day moving average of $4.98.

Analysts' average 12-month price target for AGEN is $25.00, which implies 288.20% upside from the current price. Individual estimates range from $25.00 to $25.00.

Of the 3 analysts covering Agenus Inc., 3 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Agenus Inc. has a market capitalization of $290.84M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Agenus Inc. posted a loss of $0.01 per share against an estimate of $0.045, missing expectations by 122.22%. Upcoming reports are listed in the earnings calendar.

Agenus Inc. reported revenue of $34.5M in its most recent quarter, which has increased by 34.29% compared with the same quarter a year earlier. Analysts had expected $34M.

AGEN trades at a price-to-earnings ratio of 8.8 based on its earnings over the last twelve months.

Agenus Inc. has not paid any dividends over the past year.

Companies most comparable to Agenus Inc. include Opus Genetics, Inc., Turn Therapeutics Inc., Fate Therapeutics, Inc., Zentalis Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc.

In the latest trading session AGEN moved between $6.11 and $6.82, a range of 11.02% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Agenus Inc. shows a sell rating today and a neutral rating on the weekly timeframe. Technical ratings are indicators, not investment advice.

Over the past 52 weeks AGEN has traded between $2.71 and $10.31. The current price is 37.54% below its 52-week high.